Aug. 20 at 5:23 PM
$PFE I am bullish because the latest earnings report (Q2 2026, released August 4) was genuinely strong, particularly relative to expectations. The guidance was also improved. Pfizer raised the bottom end of 2026 revenue guidance by
$1 billion. That's a positive signal because Pfizer is essentially saying its non-COVID business is performing better than previously anticipated. Pfizer is demonstrating that its underlying pharmaceutical business can grow even while COVID revenue continues disappearing.